Pacira BioSciences Announces Settlement of U.S. Patent Litigation for EXPAREL
Provided By GlobeNewswire
Last update: Apr 7, 2025
-- Fresenius Kabi licensed to sell volume-limited amounts of generic bupivacaine liposome injectable suspension in the U.S. no earlier than a confidential date in 2030 --
Read more at globenewswire.com25.9
+1.25 (+5.07%)
Find more stocks in the Stock Screener
PCRX Latest News and Analysis
7 days ago - ChartmillPACIRA BIOSCIENCES INC (NASDAQ:PCRX), a growth stock which is not overvalued.Discover PACIRA BIOSCIENCES INC, an undervalued growth gem. NASDAQ:PCRX is shining in terms of growth metrics, and it's also displaying strong financial health and profitability, retaining an appealing valuation.
15 days ago - ChartmillWondering what's happening in today's after-hours session?The US market regular session of Monday is over, let's have a look at the top gainers and losers in the after hours session today.
17 days ago - ChartmillPACIRA BIOSCIENCES INC (NASDAQ:PCRX) is an undervalued gem with solid fundamentals.PACIRA BIOSCIENCES INC is a hidden gem, featuring undervaluation and robust fundamentals. NASDAQ:PCRX showcases decent financial health and profitability, coupled with an attractive price.
